Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jordan’s Hikma Raises Full-Year Forecast As Strong Doxycycline Sales Lift Prospects

This article was originally published in PharmAsia News

Executive Summary

Hikma Pharmaceuticals PLC shrugged off turmoil in its core Middle East markets and reported strong first half sales growth, helping the company to lift full-year revenue growth guidance to around 20% from 13%. The result was lifted by a 10-fold increase in sales of antibiotic doxycycline and continued strong sales in core markets as well as the United States and Europe.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC085253

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel